What We Have Accomplished To Date:

  • ~ $2M Investment in effort to date via the University of Minnesota foundational grants and philanthropy towards the development of this Checkpoint Inhibitor
  • Our CD200 work has been informed by the two vaccine base clinical trials of GBM-6 for various types of brain cancers (total of 14 patients)
  • In all cases of the prevalence of CD200 was significant and failure was the result
  • Since then we have:
  • Demonstrated efficacy: Our human peptides demonstrated efficacy in human immune cells
  • Demonstrated efficacy of the OX2 Peptide in canine patients (outpacing current standard of care). Dogs diagnosed at the University of Minnesota veterinary hospital with high-grade gliomas are enrolled in this study. Tumors are resected and used as a tumor vaccine in combination with a canine specific CD200-peptide inhibitor. In contrast to a 11% progression free and 214 days survival using tumor vaccine alone. The use of the inhibitor resulted in 79% progression free with a 42% survival and 530 post surgery as a March 16th, 2017. Furthermore, of the 58% of dogs who went to trial, only 35% failed due to tumor related reasons.

What We Can Accomplish with $2M of funding:

  • Our goal is to complete our toxicology studies and IND submission in the next 14 to 18 months. Key milestones are noted below:
    • Determine the final/optimal single, or combination of, peptide inhibitor(s)
    • Contract out toxicology and safety studies in the peptide
    • cGMP testing of both the peptide and the modified GBM-6 vaccine
    • Complete investigational new drug (IND) applications for the 1st 2 Trials

When the above work is completed a significant positive inflection in the overall valuation of OX2 will occur!

OX2 Development Timeline

Series A Raise & Use of Funds

Capital Raise:

  • OX2 is planning a Series A financing of $2M
    • The Use of Funds for the Series A will be as follows:
      • Validate cGMP status for the OX2 Inhibitor
      • Complete Toxicology studies
      • Validate cGMP status for our humanized antibody
      • Complete and submit the 2 IND’s to the FDA
      • Patent cost

OX2’s Management team

Michael Olin, PhD
Chief Scientific Officer & Founder
  • Nine years of Translational Research
  • 15 Years of Industry Experience
Jeff Liter, M.B.A.
Interim CEO/Chief Financial Officer
  • C-Suite Executive who has profitably tripled revenues for six separate companies
  • COO of Progenitor Cell Therapy
  • CEO B-MoGen Biotech
Chris Moertel, MD
Chief Medical Officer & Founder
  • Dahlberg Professor in the University of Minnesota
  • 25 Years experience as neuro-oncologist driving several clinical trials
Sumant Dhawan, BS
VP of Operations & Founder
  • CEO Cell Technology
  • 25+ Years of Antibodies & Peptide Development

OX2’s Investigation Team

  • Dr. Michael Olin, PhD, inventor and co-founder of OX2 Therapeutics. Dr. Olin is an Assistant Professor in the Division of Pediatric Hematology and Oncology at the University of Minnesota. After completing his PhD in Infectious Diseases, he did two postdoctoral fellowships, studying the effects of opioids on tuberculosis meningitis and brain tumor immunotherapy and has more than 9 years experience in translational research with two other therapies that are in clinical trials.
  • Dr. Christopher L. Moertel, MD, co-founder of OX2 Therapeutics. Dr. Moertel is an Professor in the Division of Pediatric Hematology and Oncology and holder of the Dahlberg Professorship of Pediatric Brain Tumor Research in the University of Minnesota Medical School. Dr. Moertel has over 25 years of experience as a neuro-oncologist, directing numerous clinical trials, has served on numerous national and local professional committees and is the author of a number of book chapters, articles and abstracts. Special interests include rare pediatric tumors, neurofibromatosis-associated neoplasia, and the therapy of children with brain and spinal cord tumors.
  • Dr. David A. Largaespada, PhD, Member, OX2 Therapeutics Scientific Advisory Board. Dr. Largaespada is Professor of Cell Biology and Development Genetics and holds the Margaret Harvey Chair in Cancer Genetics at the University of Minnesota. He is also the Associate Director of the University of Minnesota Masonic Cancer Center and is Director of the Brain Tumor Program at the University of Minnesota.
  • Dr. G. Elizabeth Pluhar, D.V.M., PhD, Member, OX2 Therapeutics Scientific Advisory Board. Dr. Pluhar is a veterinary neurosurgeon and Associate Professor in the Department of Veterinary Clinical Services at the University of Minnesota. Dr. Pluhar has collaborated with Dr. Olin for more than 6 years in the development of novel immunotherapies for canines with CNS tumors and conditions affecting the brain, spinal cord, peripheral nerves and supporting structures in canines. Together, Drs. Olin and Pluhar are successfully testing the safety and efficacy of the OX2 inhibitor in a canine high-grade brain tumor clinical trial.